Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
Mastercards's Chief Technology Officer Ed McLaughlin shows Cheddar News Senior Reporter Michelle Castillo what shoppers can expect in shopping technology.
